AU2015343083B2 - Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods - Google Patents

Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods Download PDF

Info

Publication number
AU2015343083B2
AU2015343083B2 AU2015343083A AU2015343083A AU2015343083B2 AU 2015343083 B2 AU2015343083 B2 AU 2015343083B2 AU 2015343083 A AU2015343083 A AU 2015343083A AU 2015343083 A AU2015343083 A AU 2015343083A AU 2015343083 B2 AU2015343083 B2 AU 2015343083B2
Authority
AU
Australia
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
ketamine
norketamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015343083A
Other languages
English (en)
Other versions
AU2015343083A1 (en
Inventor
Nelson Landrau
Alex Nivorozhkin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acadia Pharmaceuticals Inc
Original Assignee
Acadia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharmaceuticals Inc filed Critical Acadia Pharmaceuticals Inc
Publication of AU2015343083A1 publication Critical patent/AU2015343083A1/en
Application granted granted Critical
Publication of AU2015343083B2 publication Critical patent/AU2015343083B2/en
Assigned to ACADIA PHARMACEUTICALS INC. reassignment ACADIA PHARMACEUTICALS INC. Request for Assignment Assignors: AMORSA THERAPEUTICS, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2015343083A 2014-11-04 2015-11-04 Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods Active AU2015343083B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462074645P 2014-11-04 2014-11-04
US62/074,645 2014-11-04
PCT/US2015/059113 WO2016073653A1 (en) 2014-11-04 2015-11-04 Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods

Publications (2)

Publication Number Publication Date
AU2015343083A1 AU2015343083A1 (en) 2017-06-08
AU2015343083B2 true AU2015343083B2 (en) 2020-07-23

Family

ID=55909773

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015343083A Active AU2015343083B2 (en) 2014-11-04 2015-11-04 Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods

Country Status (18)

Country Link
US (6) US10252982B2 (https=)
EP (2) EP4393487A3 (https=)
JP (2) JP6882180B2 (https=)
KR (1) KR102604397B1 (https=)
CN (2) CN115521217A (https=)
AU (1) AU2015343083B2 (https=)
CA (1) CA2966737A1 (https=)
DK (1) DK3215147T3 (https=)
ES (1) ES2977383T3 (https=)
FI (1) FI3215147T3 (https=)
HU (1) HUE066468T2 (https=)
LT (1) LT3215147T (https=)
PL (1) PL3215147T3 (https=)
PT (1) PT3215147T (https=)
RS (1) RS65411B1 (https=)
RU (1) RU2771275C2 (https=)
SI (1) SI3215147T1 (https=)
WO (1) WO2016073653A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE056378T2 (hu) 2013-09-13 2022-02-28 Univ Chiba Nat Univ Corp R-Ketamin és sójának alkalmazása gyógyszerekként
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
PL3287124T3 (pl) 2014-04-17 2023-02-20 Ketabon Gmbh Doustna postać dawkowania ketaminy
DK3215147T3 (da) * 2014-11-04 2024-04-02 Acadia Pharm Inc Neurodæmpende norketamin-forbindelser og fremgangsmåder
US11426366B2 (en) * 2015-05-15 2022-08-30 Arizona Board Of Regents On Behalf Of The Universsity Of Arizona Compositions and methods for treating motor disorders
CN107847469A (zh) 2015-06-27 2018-03-27 美国神农制药责任有限公司 氯胺酮透皮递送系统
EP3442940A1 (en) * 2016-04-11 2019-02-20 Clexio Biosciences Ltd. Deuterated ketamine derivatives
US20190256487A1 (en) * 2016-09-16 2019-08-22 BioPharmaWorks, LLC Hydroxynorketamine prodrugs
AU2017351437B2 (en) * 2016-10-27 2022-01-27 National University Corporation Chiba University Application of (S)-norketamine and salt thereof as pharmaceutical
CA3059775A1 (en) 2017-04-13 2018-10-18 Ovid Therapeutics Inc. Methods of treating developmental encephalopathies
WO2018234568A2 (en) * 2017-06-23 2018-12-27 Develco Pharma Schweiz Ag HYDROXYNORKETAMINE FOR USE IN TREATING DEPRESSION
CA3071491A1 (en) 2017-07-31 2019-02-07 Small Pharma Ltd Crystalline forms of hydroxynorketamine
US12090123B2 (en) 2017-10-10 2024-09-17 Douglas Pharmaceuticals Ltd. Extended release pharmaceutical formulation
CN111630026A (zh) * 2017-10-10 2020-09-04 道格拉斯制药有限公司 缓释药物制剂和治疗方法
US11471415B2 (en) 2017-10-10 2022-10-18 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation and methods of treatment
US10869838B2 (en) 2017-10-10 2020-12-22 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
US10441544B2 (en) 2017-10-10 2019-10-15 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
WO2022064387A1 (en) * 2020-09-24 2022-03-31 Douglas Pharmaceuticals Ltd. Extended release pharmaceutical formulation
EP3501503A1 (en) * 2017-12-22 2019-06-26 Cosmo Technologies Ltd. Solid delivery composition
ES2907692T3 (es) 2017-12-29 2022-04-26 Celon Pharma Sa Composición de ketamina de polvo seco para su administración por vía pulmonar en la depresión resistente al tratamiento
US11980595B2 (en) 2018-02-15 2024-05-14 National University Corporation Chiba University Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases
WO2019213551A1 (en) 2018-05-04 2019-11-07 Perception Neuroscience, Inc. Methods of treating substance abuse
BR112020023882A2 (pt) 2018-06-27 2021-02-09 Clexio Biosciences Ltd. método para tratar transtorno depressivo maior
CN112702995A (zh) 2018-10-05 2021-04-23 克雷西奥生物科技有限公司 治疗重度抑郁症的艾氯胺酮的治疗方案
EP3863617A1 (en) 2018-10-11 2021-08-18 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
KR20220002905A (ko) * 2019-03-25 2022-01-07 더글라스 파머수티클스 리미티드 서방형 약학 제제
US12589083B2 (en) 2019-05-07 2026-03-31 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
CA3148992A1 (en) * 2019-08-06 2021-02-11 The Regents Of The University Of California Scaleable preparation of polyketides
EP4041209A4 (en) 2019-10-11 2024-01-24 Pike Therapeutics, Inc. TRANSDERMAL COMPOSITIONS COMPRISING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF EPILEPTIC DISORDERS
EP4084786A1 (en) 2019-12-30 2022-11-09 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
JP2023507926A (ja) 2019-12-30 2023-02-28 クレキシオ バイオサイエンシーズ エルティーディー． 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
WO2021137148A1 (en) * 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating neuropsychiatric or neurological conditions
MX2022014599A (es) * 2020-05-20 2022-12-16 Certego Therapeutics Inc Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.
CN114524737B (zh) * 2020-11-23 2024-10-22 江苏恒瑞医药股份有限公司 一种取代的环己酮类化合物
GB202019952D0 (en) * 2020-12-17 2021-02-03 Neurocentrx Pharma Ltd Novel compositions
US20240207338A1 (en) * 2021-04-30 2024-06-27 Progressive Therapeutics Inc Ketamine and cannabis for the treatment of emotional disorders
CN116730853A (zh) * 2022-03-04 2023-09-12 上海致根医药科技有限公司 新型氨基酮类化合物及其制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004045601A1 (en) * 2002-11-18 2004-06-03 Yaupon Therapeutics, Inc. Analgesic uses of norketamine and ketamine/norketamine prodrugs
US20080268071A1 (en) * 2007-04-26 2008-10-30 Auspex Pharmaceuticals, Inc. Substituted cyclohexanones

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250732A (en) 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US20100076087A1 (en) * 2005-10-06 2010-03-25 Auspex Pharmaceuticals, Inc. Methods of reduction of interpatient variability
US8765178B2 (en) * 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
WO2009131794A1 (en) * 2008-03-27 2009-10-29 University Of Kentucky Research Foundation Opioid-ketamine and norketamine codrug combinations for pain management
CA2922507C (en) 2013-08-26 2022-07-05 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
DK3215147T3 (da) 2014-11-04 2024-04-02 Acadia Pharm Inc Neurodæmpende norketamin-forbindelser og fremgangsmåder

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004045601A1 (en) * 2002-11-18 2004-06-03 Yaupon Therapeutics, Inc. Analgesic uses of norketamine and ketamine/norketamine prodrugs
US20080268071A1 (en) * 2007-04-26 2008-10-30 Auspex Pharmaceuticals, Inc. Substituted cyclohexanones

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DUMONT ET AL, "Prospects in the use of deuterated molecules as therapeutic agents", REVUE, INSTITUT NATIONAL DES RADIOELEMENTS, BELGIUM, (1982-01), vol. 6, no. 4, ISSN 0770-1160, pages 2 - 10 *
EBERT B ET AL, "Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord", EUROPEAN JOURNAL OF PHARMACOLOGY, (1997-08-20), vol. 333, no. 1, pages 99 - 104 *
FOSTER A B, "Deuterium isotope effects in the metabolism of drugs and xenobiotics: implications for drug design", ADVANCES IN DRUG RESEA, ACADEMIC PRESS, LONDON, GB, (1985-01), vol. 14, ISSN 0065-2490, pages 1 - 40 *
LEUNG ET AL, "Comparative pharmacology in the rat of ketamine and its two principal metabolites, norketamine and (Z)-6-hydroxynorketamine", JOURNAL OF MEDICINAL CHEMISTRY, (1986-01), vol. 29, no. 11, pages 2396 - 2399 *
NORLIDA HARUN ET AL, "Validation of an Enzyme-Linked Immunosorbent Assay Screening Method and a Liquid Chromatography-Tandem Mass Spectrometry Confirmation . . .", JOURNAL OF ANALYTICAL TOXICOLOGY, (2009-07), vol. 33, no. 6, pp 310 - 321 *
REGISTRY, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, (2013-06-07), Database accession no. 1435934-57-8 *
ROHIDAS S SULAKE ET AL, "Synthesis of deuterium labeled ketamine metabolite dehydronorketamine-", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 21, no. 19, pages 5719 - 5721, (2011-08-08) *
YARNELL, "Heavy-Hydrogen Drugs Turn Heads, Again", INTERNET CITATION, (2009-06-22), pages 36 - 39, URL: http://pubs.acs.org/cen/science/87/8725sci1.html, (2009-09-16) *
ZHAO XIAOCHEN ET AL, "Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment - resistant bipolar depression", BRITISH JOURNAL OF CLINICAL PHARMACOL, vol. 74, no. 2, pp 304 - 314 *

Also Published As

Publication number Publication date
CN115521217A (zh) 2022-12-27
US20220106258A1 (en) 2022-04-07
DK3215147T3 (da) 2024-04-02
EP4393487A3 (en) 2024-08-21
PT3215147T (pt) 2024-04-18
JP2018501299A (ja) 2018-01-18
US10981859B2 (en) 2021-04-20
EP3215147B1 (en) 2024-02-28
FI3215147T3 (fi) 2024-04-18
EP3215147A4 (en) 2018-05-30
US20260109663A1 (en) 2026-04-23
US20230192593A1 (en) 2023-06-22
HUE066468T2 (hu) 2024-08-28
ES2977383T3 (es) 2024-08-22
EP4393487A2 (en) 2024-07-03
US20170355663A1 (en) 2017-12-14
RS65411B1 (sr) 2024-05-31
CN107106529A (zh) 2017-08-29
US20190263749A1 (en) 2019-08-29
CA2966737A1 (en) 2016-05-12
US11613515B2 (en) 2023-03-28
US10252982B2 (en) 2019-04-09
RU2017119222A3 (https=) 2019-06-07
US11603348B2 (en) 2023-03-14
PL3215147T3 (pl) 2024-06-24
KR20170083575A (ko) 2017-07-18
JP6882180B2 (ja) 2021-06-02
LT3215147T (lt) 2024-04-25
US12466783B2 (en) 2025-11-11
KR102604397B1 (ko) 2023-11-21
JP2021120389A (ja) 2021-08-19
EP3215147A1 (en) 2017-09-13
RU2771275C2 (ru) 2022-04-29
WO2016073653A1 (en) 2016-05-12
AU2015343083A1 (en) 2017-06-08
US20220402863A1 (en) 2022-12-22
RU2017119222A (ru) 2018-12-06
SI3215147T1 (sl) 2024-05-31

Similar Documents

Publication Publication Date Title
AU2015343083B2 (en) Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods
USRE50805E1 (en) Single-layer oral dose of neuro-attenuating ketamine
KR20240088949A (ko) 질병 및 질환의 치료를 위한 lsd 유도체, 합성 및 방법
WO2023028091A1 (en) Deuterated empathogens
US20120046302A1 (en) Methods of treating cns disorders
US20040266864A1 (en) Methods for treating depression and other CNS disorders using enantiomerically enriched desmethyl-and didesmethyl-metabolites of citalopram
WO2010126527A1 (en) Methods of treating cns disorders
US20250339403A1 (en) Tryptamine Formulations and Uses Thereof
US9763904B2 (en) Position-specific asymmetric deuterium enriched catecholamine derivatives and medicaments comprising said compounds

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ACADIA PHARMACEUTICALS INC.

Free format text: FORMER OWNER(S): AMORSA THERAPEUTICS, INC.